The global nausea medicine market Growth Accelerated by increasing prevalence of nausea induced by medication
Nausea medicine provide relief from nausea and vomiting caused due to various factors like motion sickness, pregnancy, chemotherapy, and gastrointestinal disorders. Growing prevalence of diseases inducing nausea along with rising number of patients receiving chemotherapy or undergoing surgery has increased demand for effective anti-emetic drugs. These factors support growth of the global nausea medicine market.
The global nausea
medicine market size is estimated to be valued at US$ 2.8 Bn in 2023 and is
expected to exhibit a CAGR of 6.3% over the forecast period 2023 to 2030, as
highlighted in a new report published by Coherent Market Insights.
Market key trends:
The increasing prevalence of nausea induced due to medications have accelerated
demand for effective nausea medications. It is observed that chemotherapy
inducing drugs are major cause of nausea in cancer patients undergoing
treatment. Around 70-80% patients receiving highly emetogenic chemotherapy
experience vomiting and nausea. Growing cancer incidence worldwide have
increased number of patients requiring chemotherapy. This has considerably
boosted development and demand for 5-HT3 receptor antagonists along with NK1
receptor antagonists, which are majorly used for chemotherapy induced nausea.
Manufacturers are engaged in developing these antiemetic drugs with improved
efficacy and tolerability to cater needs of growing cancer patient pool.
Segment Analysis
The global nausea medicine market is dominated by the over-the-counter (OTC)
segment. This can be attributed to the easy availability and low prices of OTC
nausea medicines that make them the medicines of first choice for patients with
mild symptoms. However, the prescription medicines segment is expected to grow
at a higher pace during the forecast period due to the increasing demand for
more effective drugs to treat severe nausea.
Key Takeaways
The global nausea medicine market is expected to witness high growth. The
global nausea medicine market size is estimated to be valued at US$ 2.8 Bn in
2023 and is expected to exhibit a CAGR of 6.3% over the forecast period 2023 to
2030.
Key players
Key players operating in the nausea medicine market are GlaxoSmithKline plc., Pfizer Inc., Novartis International AG, Sanofi S.A., Merck & Co., Inc., Johnson & Johnson, Bayer AG, Takeda Pharmaceutical Company Limited, AstraZeneca plc., and Eli Lilly and Company.
Comments
Post a Comment